Buy 5 or more, save 35% · code

Back to Catalog

Peptides

Semax 10 mg

$79Per Unit

Synthetic neuroactive peptide stabilized with Pro-Gly-Pro tripeptide sequence. Synthesized to high analytical purity with comprehensive verification.

Lot SMX2026-06F · COA on request
Lyophilized peptide, sterile vial, 10 mg fill
2–8°C

1 × $79.00 = $79.00

4 more units of anything - mix and match - unlocks 35% off with code EHAB35.

Semax 10 mg

$79.00

Research use only
Semax 10 mg research packaging
Lyophilized peptide, sterile vial, 10 mg fill
Anubis Research Labs

Documentation

The certificate of analysis for the current lot (Lot SMX2026-06F) is sent on request, so you can review identity and purity testing before you order.

Request the lot COA

Research summary

Semax(ACTH(4-10) analog)

Regulatory status
Not approved in the U.S. FDA lists semax among substances that may present significant safety risks in compounding.
Strongest evidence
Animal studies; little English-language human data
Overview

Semax is a synthetic heptapeptide based on a fragment of ACTH, developed in Russia and studied for neuroprotection.

What researchers study it for
  • Neuroprotection and recovery after nervous-system injury (animal models)
Mechanism

Proposed neurotrophic and neuro-immune effects in animal studies.

Evidence (2)
  1. Animal study

    Spinal cord injury in mice (Br J Pharmacol 2025)

    Promoted functional recovery after spinal cord injury in a mouse model, linked to the mu-opioid receptor gene pathway.[1]

  2. Animal study

    Early-life drug exposure in rats (2021)

    Attenuated behavioral and neurochemical changes after early-life fluvoxamine exposure.[2]

Limitations of the evidence
  • Independent human trials are lacking.
  • Products on this site are sold for laboratory research only. They are not the medicines used in the trials above, and those results do not apply to research material.
Sources (3)
  1. 1.Semax peptide targets the mu opioid receptor gene Oprm1 to promote functional recovery after spinal cord injuryLiu R et al. Br J Pharmacol. 2025 Animal study
  2. 2.Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposureGlazova NY et al. Neuropeptides. 2021 Animal study
  3. 3.Certain bulk drug substances for use in compounding that may present significant safety risks (lists semax)U.S. FDA, page current as of Apr 22, 2026 Regulatory
Every published studyPubMed search: Semax(opens in a new tab)Every registered trialClinicalTrials.gov search: Semax(opens in a new tab)

Reviewed 2026-10-02. Summaries describe published research and regulatory records; they are not medical advice and do not describe how to use this product. Sold for laboratory research use only.